Elvan Işık

Dr. Elvan Işık

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2011 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
PDF file
GAGulfidan Aras
Gulfidan Aras
FKFigen Kadakal
Figen Kadakal
SPSevim Purisa
Sevim Purisa
DKDilek Kanmaz
Dilek Kanmaz
AAAysun Aynaci
Aysun Aynaci
EIElvan Işık
Elvan Işık
A few previous studies have reported that the patients with chronic obstructive pulmonary disease (COPD) have a 29.1% to 36.8% frequency of restless legs syndrome (RLS). In this study, we observed RLS symptoms in patients experiencing COPD exacerbation to better understand the relationship between the many clinical parameters of COPD and the presence of RLS and to attract the attention of specialists on the association between the two conditions. Twenty-two male patients in COPD exacerbation; 17 healthy individuals were evaluated in this study. The patients were evaluated using the 2003 RLS symptom criteria outlined by the International Restless Legs Syndrome Study Groups (IRLSSG). The Pittsburgh Sleep Quality Index and Epworth daytime sleepiness scale were used to assess the sleep quality of patients. The RLS symptoms were correlated with blood levels of laboratory and clinical parameters. Statistical analyses were performed using SPSS 17.0 statistical software packet. The Pittsburgh Sleep Quality Index and Epworth daytime sleepiness scale scores were increased in COPD patients and correlated significantly with RLS symptoms. It was found that 54.5% of COPD patients with acute exacerbations were observed to have RLS symptoms. The Pittsburgh Sleep Quality Index was significantly higher in COPD patients with RLS symptoms compared to COPD patients without RLS symptoms (p < 0.05). We did not observe any significant difference in the previously reported metabolic and clinical parameters associated with RLS in COPD patients with and without RLS. RLS symptoms increase during COPD exacerbation and lead to decreased sleep quality.

13 April 2026 in Liver Transplantation
Verified
Journal Article
Closed access
KMKenan Moral
Kenan Moral
MHMURAT HARPUTLUOGLU
MURAT HARPUTLUOGLU
GÖGülşah Fidan Özkumur
Gülşah Fidan Özkumur
DGDOĞAN CAN GAVCAR
DOĞAN CAN GAVCAR
EEEfe Erbay
Efe Erbay
GKGökhan Kabacam
Gökhan Kabacam
The Model for End-stage Liver Disease Sodium (MELD-Na) score predicts mortality in liver transplant candidates. MELD 3.0 has been proposed as an improved model for estimating mortality risk. This study evaluated MELD 3.0’s predictive accuracy for short-term mortality among Turkish liver transplant candidates and compared its performance with MELD and MELD-Na scores. Patients listed both for deceased donor transplants and living donor transplants were analyzed in the study. The discriminative abilities of MELD, MELD-Na, and MELD 3.0 scores were assessed using the area under the receiver operating characteristic curve (AUROC). Comparisons between AUROC values used the DeLong test. The most predictive cutoff for MELD 3.0 was determined using the Youden index. Transplant-free survival was analyzed using the Kaplan–Meier method, with survival curves compared using the log-rank test. A total of 1689 patients were included in this nationwide, multicenter study. Hepatitis B was the leading cause of cirrhosis (29%, n=491), followed by metabolic dysfunction–associated steatohepatitis (20%, n=335). For 3-month mortality, MELD 3.0 had the highest AUROC (0.753), followed by MELD-Na (0.747) and MELD (0.725). The most predictive cutoff values were 18 for MELD and 21 for MELD-Na and MELD 3.0. Both MELD-Na and MELD 3.0 outperformed MELD ( p <0.001), but showed no significant difference between them ( p =0.17). MELD 3.0 and MELD-Na demonstrated superior performance to MELD in predicting 3-month mortality among Turkish liver transplant candidates, though their predictive accuracy was comparable. Further refinements are needed to enhance MELD 3.0’s clinical utility.

15 October 2019 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
NDNilay Danis
Nilay Danis
FTFatih Tekin
Fatih Tekin
UAUlus Salih Akarca
Ulus Salih Akarca
NÜNALAN GÜLSEN ÜNAL
NALAN GÜLSEN ÜNAL
EIElvan Işık
Elvan Işık
FGFulya Günşar
Fulya Günşar
Background/Aims: This study aimed to compare the causes of nonvariceal upper gastrointestinal bleeding (NVUGB), demographics, risk factors, and outcomes of patients during two periods between 1993 and 2016 in a tertiary health-care center in Turkey. Materials and Methods: We compared the causes of NVUGB and clinical outcomes in 421 patients hospitalized between January 1993 and December 1995 with those of 231 patients with NVUGB hospitalized between January 2015 and September 2016. We also compared epidemiological characteristics, risk factors, and the rates of endoscopic hemostatic procedures. Results: We observed significant increases in patients’ mean age, in the percentage of patients with comorbid conditions, and in the percentage of patients who received direct-acting oral anticoagulants before bleeding. We also observed a statistically nonsignificant increase in the diagnoses of gastric ulcer, along with a significant concordant decrease in diagnoses of duodenal ulcer as a cause of bleeding. The use of emergency surgical hemostasis decreased among cases of peptic ulcer bleeding. The overall rate of mortality from bleeding did not significantly change between the two periods. Conclusion: Over the 23 years studied, the causes of NVUGB changed, probably because the population was increasingly elderly population and because of the use of anticoagulants and better therapeutic approaches to chronic duodenal ulcers. The use of emergency surgical hemostasis reduced, but mortality rate did not significantly change between the two specific periods.

11 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ACAli Rıza Calıskan
Ali Rıza Calıskan
ITIlker Turan
Ilker Turan
SVSezgin Vatansever
Sezgin Vatansever
JWJasmin Weninger
Jasmin Weninger
EŞEmine Türkmen Şamdancı
Emine Türkmen Şamdancı
FGFulya Günşar
Fulya Günşar
Background and Aims: Ornidazole, a nitroimidazole antibiotic, is widely used for protozoal and anaerobic infections and is generally considered safe. However, ornidazole-induced liver injury (OILI) is an underrecognized yet potentially severe adverse reaction. This multicenter study aims to characterize the clinical features, histopathology, and outcomes of OILI to improve the awareness and management of this rare entity worldwide. Methods: We conducted a retrospective analysis of 101 patients with OILI from eight tertiary centers between 2006 and 2023. Cases were included based on liver enzyme elevations temporally linked to ornidazole and the exclusion of other causes. Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) score. Clinical data, laboratory parameters, autoantibody profiles, histology, treatments, and outcomes were evaluated. Results: OILI was classified as highly probable in 42.6% of cases (n = 43), probable in 51.5% of cases (n = 52), and possible in 5.9% (n = 6) of cases. The predominant pattern was acute hepatocellular injury (83.2%) (n = 84). Autoimmune-like hepatitis occurred in 5% of cases (n = 5), with ANA positivity in 16.8% of cases (n = 17). Corticosteroids were used in 24.8% of cases (n = 25) and were associated with higher ANA positivity and a 20% (n = 5) relapse rate post-discontinuation. Recovery was achieved in 87.7% of cases (n = 88), while 7.9% of cases (n = 8) required liver transplantation and 4% (n = 4) died. Conclusions: Ornidazole can cause serious idiosyncratic liver injury, including autoimmune phenotypes, and should be considered in the differential diagnosis of acute hepatitis. Given the notable risk of liver failure and death, early recognition, drug discontinuation, and close monitoring are essential. In select cases, corticosteroids and plasmapheresis may be beneficial, though the evidence remains limited.

6 January 2026 in Clinical Transplantation
Verified
Journal Article
Closed access
GAGupse Adali
Gupse Adali
SENCAN ACARSENCAN ACAR
SENCAN ACAR
MHMURAT HARPUTLUOGLU
MURAT HARPUTLUOGLU
TYTonguc Utku Yilmaz
Tonguc Utku Yilmaz
HKHamdi Karakayalı
Hamdi Karakayalı
RIRamazan Idilman
Ramazan Idilman

1 January 2026 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
SŞSemiha Şimşek
Semiha Şimşek
EIElvan Işık
Elvan Işık
Betül Çiğdem YortanlıBetül Çiğdem Yortanlı
Betül Çiğdem Yortanlı
CÇCem Çekiç
Cem Çekiç
Objectives: PADI‐4 is a member of the peptidyl arginine deiminase enzyme family. This enzyme is expressed by inflammatory cells and plays an important role in inflammation and immune responses. In this study, we aimed to evaluate serum PADI‐4 levels in patients with ulcerative colitis (UC) and to investigate the relationship between PADI‐4 and disease activity. Material and Method: Fifty‐one patients with UC and 31 healthy controls were included in this observational study. First, serum PADI‐4 levels in patients with UC and the control group were compared. Subsequently, serum PADI‐4 levels were analyzed in UC patients with active disease and those who are in remission, separately. Finally, the impact of PADI‐4 on predicting disease activity was evaluated by performing correlation analyses between serum PADI‐4 and C‐reactive protein (CRP) in addition to the total Mayo score (TMS) and modified Mayo Endoscopic Subscore (MESS). Results: Serum mean PADI‐4 levels were found to be significantly higher in the UC group (1317 ± 818 pg/mL) compared to the control group (873 ± 622 pg/mL) ( p : 0.009). Serum mean PADI‐4 levels were significantly different between the three groups (patients with remission, mild disease, and moderate/severe disease group) ( p : 0.015) (1076 ± 609, 1073 ± 683, and 1802 ± 943 pg/mL, respectively). In Spearman′s correlation analysis, it was determined that there was a positive and significant relationship between PADI‐4 and CRP levels ( r = 0.31, p : 0.027) in addition to TMS ( r = 0.419, p : 0.02) and MESS ( r = 0.417, p : 0.002). The ideal serum PADI‐4 levels for predicting disease activity were found to be 980 pg/mL. Conclusion: Our study revealed that serum PADI‐4 levels were higher in patients with UC compared to healthy controls and might be an effective marker to determine disease severity.